Practical Neurology

12/05/2025

New findings from ancillary US studies show structured lifestyle interventions linked to apnea, health, and resilience in older adults at risk for ’s— https://ow.ly/AyF250XCsbo
CTAD Conference Alzheimer's Association American Academy of Neurology (AAN)

New findings from 3 ancillary studies to the US POINTER trial (NCT03688126)—presented at the 18th annual Clinical Trials in Alzheimer’s Disease (CTAD) con…

12/04/2025

The diagnostic accuracy of 's plasma assay for 's pathology was assessed in a real-world cohort in a study presented at .
https://ow.ly/2MaP50XC6RG
U.S. Food and Drug Administration CTAD Conference American Academy of Neurology (AAN) Alzheimer's Association

A study presented at the 18th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference evaluated the Food and Drug Administration (FDA)-cleared and…

12/04/2025

Treatment with the anti- antibody in people with dominantly inherited disease was associated with substantial reductions in the novel eMTBR-tau243, indicating strong target engagement. https://ow.ly/HIi950XBIfI
CTAD Conference American Academy of Neurology (AAN) Alzheimer's Association Eisai Global

Treatment with the investigational anti-tau antibody etalanetug (E2814; Eisai, Tokyo, Japan) for individuals with dominantly inherited Alzheimer disease (…

12/03/2025

LM11A-31, a p75 neurotrophin receptor modulator, reduced p- and preserved visuospatial function in disease, with proteomic changes linked to synaptic biology. Data presented at .
https://ow.ly/BKX450XBBz0
CTAD Conference Alzheimer's Association American Academy of Neurology (AAN)

Modulation of the p75 neurotrophin receptor using LM11A-31 (PharmatrophiX, Menlo Park, CA), an investigational small molecule agent, may slow disease-rela…

12/03/2025

At , Takeshi Iwatsubo, MD, PhD was honored as the recipient of this year’s Lifetime Achievement Award in ’s Disease Therapeutic Research. https://ow.ly/ERu250XAYKh
CTAD Conference Alzheimer's Association National Center of Neurology and Psychiatry - 国立精神・神経医療研究センター

Takeshi Iwatsubo, MD, PhD was recognized at the 18th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference as the recipient of this year’s Lifet…

12/03/2025

An oral oligomer-targeting treatment was associated with cognitive and functional benefits in APOE ε4 homozygotes with MCI, according to results presented at
https://ow.ly/CBLE50XAY82
Alzheon CTAD Conference Alzheimer's Association

Results of a study evaluating the efficacy and safety of the oral amyloid oligomer-targeting agent ALZ-801 (valiltramiprosate; Alzheon, Framingham, MA) in…

11/30/2025

In Lennox-Gastaut syndrome, approaches—including , , and —offer substantial, durable reduction when medications fail. Dr Edmonds discusses these strategies in an article: https://ow.ly/iuER50XyrNL
American Epilepsy Society American Academy of Neurology (AAN) Seattle Children's

11/29/2025

An individual with progressive gait, cognitive, and cranial nerve symptoms had imaging consistent with intracranial hypotension, but repeated CTM/DSM found no leak. A fractured implant was identified as the cause in a case report by Drs. Kushwah, Tiwari, Chhabra, Bhalla, Bhaskar, and Panda.
https://ow.ly/vr1W50Xyrur
AIIMS Jodhpur American Academy of Neurology (AAN) American Association of Neurological Surgeons CSF Leak Association - The Cerebrospinal Fluid Leak Charity

11/28/2025

The U.S. Food and Drug Administrationhas approved (Novartis) for people aged ≥2 years with and an SMN1 mutation—expanding gene-replacement therapy options for .
https://ow.ly/TGlJ50XyrFQ
Cure SMA SMA News Today American Academy of Neurology (AAN) Child Neurology Society

The Food and Drug Administration has approved Itvisma (onasemnogene abeparvovec-brve; Novartis, Basel, Switzerland) for the treatment of people aged 2 yea…

11/27/2025

Once-daily + therapy reduced risk vs placebo with no rise in ISTH major bleeding in people with noncardioembolic ischemic stroke or high-risk TIA.
https://ow.ly/UpUO50Xyr7Z
American Heart Association Endovascular Today

For people with noncardioembolic ischemic stroke or high-risk transient ischemic attack (TIA), once-daily treatment with asundexian (Bayer, Berlin, German…

11/26/2025

Strategies for managing drug-resistant are expanding with advances in less-invasive surgery—innovations in , laser ablation, and are broadening candidacy. Drs. Gallagher and Fallah review these technologies and their applications: https://ow.ly/JP2b50XypG6
American Epilepsy Society American Academy of Neurology (AAN) American Association of Neurological Surgeons UCLA David Geffen School of Medicine at UCLA

11/26/2025

Updated consensus guidelines for the use of peripheral nerve stimulation in chronic and certain indications have been published by the American Society of Pain & Neuroscience.
https://ow.ly/Kkz450XxRL9
American Academy of Neurology (AAN)

A multidisciplinary expert panel convened by the American Society of Pain and Neuroscience has released updated consensus guidelines on the use of periphe…